Live news related to DBV TECHNOLOGIES stock (FR0010417345): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on DBV TECHNOLOGIES mainly cover analyst notes, M&A activity et earnings publications. The stock trades at €2,75 on Euronext Paris, down 3,31% at the last update. This page lists the articles published on DBV TECHNOLOGIES stock to track the share price, company announcements and any item likely to influence market perception.
The French biotech company continues to decline at mid-session, contrary to a well-oriented Parisian market. The stock is sinking in the lower part of…
DBV Technologies announced on Monday new positive data from its phase 3 VITESSE study and introduced the protocol of its phase 2 THRIVE study, both fo…
French biotech company DBV Technologies will participate on June 9 in the 47th annual Global Healthcare Conference organized by Goldman Sachs in Miami…
The French biotech company experiences another session of decline, while the Paris market also closes in negative territory. The stock continues its s…
DBV Technologies announces the screening of the first participant in the phase 2 THRIVE clinical study, which assesses the efficacy and safety of the …
The French biotech company falls midday, bucking the trend of a well-oriented SBF 120. The stock breaks a closely watched technical threshold downward…
The French biotech company sees a significant midday decline in a mostly stable SBF 120 market. The stock approaches a closely watched technical thres…
The French biotech is losing ground in a downward trending Parisian market. The stock has fallen below its short-term moving averages after a recent, …
DBV Technologies stock moves forward in mid-session in a well-oriented Parisian market. However, the French biotech remains down for the week and belo…
DBV Technologies shares gained 1.78% to €3.44 in mid-afternoon trading, within an SBF 120 index up by 0.84%. The French biotech's stock partially reco…
